Decreased expression of PAI-2 mRNA and protein in pregnancies complicated with intrauterine fetal growth retardation

Thrombosis and Haemostasis

Volumn 76, Issue 5, 1996, Pages 761-767

  Grancha, Salvador ^a   Estellés, Amparo ^a   Gilabert, Juan ^a   Chirivella, Melitina ^a   España, Francisco ^a   Aznar, Justo ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PLACENTA PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 2;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTRAUTERINE GROWTH RETARDATION; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYNCYTIOTROPHOBLAST; TROPHOBLAST;

EID: 0029859252     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650657     Document Type: Article

References (40)

1. Kliman HJ, Contifaris C, Feinberg RF, Strauss III JF. Implantation: In Vitro Models Utilizing Human Tissues. In: Implantation. Yoshinaga K, ed. Adams Blastocyst Publishing Group Ltd, Boston, 1989; pp 83-91.
2. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemostas Thromb 1988; 9: 87-115,
3. Ny T, Leonardsson G, Peng XR, Hägglund AC, Ny A, Liu K. Role of Plasminogen Activators and Their Inhibitors in Ovulation and Reproduction. In: Fibrinolytic inhibitors. Cellular, biological and clinical aspects. Aznar J, Gilabert J, Estellés A, eds. Garsi-Masson, Spain, 1994; pp 32-42.
4. Gilabert J, Estellés A, Grancha S, España F, Aznar J. Fibrinolytic system and reproductive process with special reference to fibrinolytic failure in preeclampsia. Human Reproduction 1995; 10: 121-31.
5. Kruithof EKO. Plasminogen activator inhibitor type 1. Biochemical, biological and clinical aspects. Fibrinolysis 1988; 2: 59-70.
6. Loskutoff DJ. Regulation of PAI-1 gene expression. Fibrinolysis 1991; 5: 197-206.
7. Astedt B, Lecander I, Ny T. The placental type plasminogen activator inhibitor, PAI-2. Fibrinolysis 1987; 1: 281-5.
8. Kruithof EKO, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995; 86: 4007-24.
9. Bachmann F. The enigma PAI-2. Gene expression, evolutionary and functional aspects. Thromb Haemost 1995; 74: 172-9.
10. Kawano T, Morimoto K, Uemura Y. Partial purification and properties of urokinase inhibitor from human placenta. J Biochem 1970; 67: 333-42.
11. Philips M, Juul AG, Thorsen S, Selmer J, Zeuthen J. Immunological relationships between the fast-acting plasminogen activator inhibitors from plasma, blood platelets and endothelial cells demonstrated with a monoclonal antibody against an inhibitor from placenta. Thromb Haemost 1986; 55: 213-7.
12. Estellés A, Gilabert J, Keeton M, Eguchi Y, Aznar J, Grancha S, España F, Loskutoff DJ, Schleef RR. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Blood 1994; 84: 143-50.
13. Dear AE, Medcalf RL. The cellular and molecular biology of plasminogen activator inhibitor type-2. Fibrinolysis 1995; 9: 321-30.
14. Hathaway W, Bonnar J. Hemostatic Alterations in Hypertensive and Placental Insufficiency Disorders of Pregnancy. In: Hemostatic Disorders of the Pregnant Woman and Newborn Infant. Hathaway W, Bonnar J, eds. John Wiley & Sons, New York, 1987; pp 185-201.
15. Cunninghan FG, MacDonald PC, Gant NF. In: Williams' Obstetrics, Eighteenth Edition. Appleton & Lange. Connecticut/San Mateo, CA, Norwalk, 1987.
16. Kruithof EKO, Tran-Thang C, Gudinchet A, Havert J, Nicoloso G, Genton C, Welti H, Bachmann F. Fibrinolysis in pregnancy: A study of plasminogen activator inhibitors. Blood 1987; 69: 460-6.
17. Estellés A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 1989; 74: 1332-8.
18. Estellés A, Gilabert J, Andrés C, España F, Aznar J. Plasminogen activator inhibitor type 1 and plasminogen activators in amniotic fluid during pregnancy. Thromb Haemost 1990; 64: 281-5.
19. Lindoff C, Lecander I, Astedt B. Fibrinolytic components in individual consecutive plasma samples during normal pregnancy. Fibrinolysis 1993; 7: 190-4.
20. Aznar J, Gilabert J, Estellés A, España F. Fibrinolytic activity and protein C in preeclampsia. Thromb Haemost 1986; 55: 314-7.
21. Gilabert J, Estellés A, Aznar J, España F, Andrés C, Santos T, Vallès J. Contribution of platelets to increased plasminogen activator inhibitor type 1 in severe preeclampsia. Thromb Haemost 1990; 63: 361-6.
22. Estellés A, Gilabert J, España F, Aznar J, Galbis M. Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia. Am J Obstet Gynecol 1991; 165: 138-42.
23. Ballegeer V, Spitz B, Kieckens L, Moreau H, Van Assche A, Collen D. Predictive value of increased plasma levels fibronectine in gestational hypertension. Am J Obstet Gynecol 1989; 161: 432-6.
24. de Boer K, Lecander J, ten Cate JW, Bom JJJ, Treffers PE. Placental type plasminogen activator inhibitor in preeclampsia. Am J Obstet Gynecol 1988; 158: 518-22.
25. Koh SCL, Anandakumar C, Montan S, Ratnam SS. Plasminogen activators, plasminogen activator inhibitors and markers of intravascular coagulation in pre-eclampsia. Gynecol Obstet Invest 1993; 35: 214-21.
26. Reith A, Booth NA, Moore NR, Cruickshank DJ, Bennett B. Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, preeclampsia and hydatidiform mole. Br J Obstet Gynecol 1993; 100: 370-4.
27. Lindoff C, Astedt B. Plasminogen activator of urokinase type and its inhibitor of placental type in hypertensive pregnancies and in intrauterine growth retardation: possible markers of placental function. Am J Obstet Gynecol 1994; 171: 60-4.
28. Halligan A, Bonnar J, Sheppard B, Darling M, Walshe J. Haemostatic fibrinolytic and endothelial variables in normal pregnancies and preeclampsia. Br J Obstet Gynecol 1994; 101: 488-92.
29. Estellés A, Gilabert J, Aznar J, España F, Schleef RR, Loskutoff DJ. Cellular Expression and Potential Roles of Plasminogen Activator Inhibitors in Normal and Pathological Pregnancies.In: Fibrinolytic inhibitors. Cellular, biological and clinical aspects. Aznar J, Gilabert J, Estellés A, eds. Garsi-Masson, Spain, 1994; pp 43-59.
30. Gilabert J, Estellés A, Ayuso MJ, España F, Chirivella M, Grancha S, Micó JM, Aznar J. Evaluation of plasminogen activators and plasminogen activator inhibitors in plasma and amniotic fluid in pregnancies complicated with intrauterine fetal growth retardation. Gynecol Obstet Invest 1994; 38: 157-62.
31. Feinberg RF, Kao L-C, Haimowitz JE, Queenan, Jr JT, Wun T-C, Strauss III JF, Kliman HJ. Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. PAI-1 is an immunocytochemical marker of invading trophoblasts. Lab Invest 1989; 61: 20-6.
32. Ott WJ: The diagnosis of altered fetal growth. Obstet Gynecol Clin North Am 1988; 15: 237-62.
33. Canavagh D, Kmuppel LA. Preeclampsia and Eclampsia. In Principles and Practice of Obstetrics and Perinatology. Iffy L, Kaminetzky H, eds. John Wiley & Sons, New York, 1981; pp 1271-89.
34. Grancha S, Estellés A, Gilabert J, España F, Aznar J. PAI-1 and PAI-2 mRNA detection in human placental extracts with digoxigenin-based non-radioactive methods. Rev Iberoamer Tromb Hemostasia 1995; 8: 145-9.
35. Ye RD, Wun T Sadler JE. cDNA cloning and expression in Escherichia coli of a plasminogen activator inhibitor from human placenta. J Biol Chem 1987; 262: 3718-25.
36. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol, chloroform extraction. Anal Biochem 1987; 162: 156-9.
37. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type I plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
38. Kumar S, Baglioni C. Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J Biol Chem 1991; 266: 20960-4.
39. Dickinson JL, Bates EJ, Ferrante A, Antalis TM. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alfa-induced apoptosis - Evidence for an alternate biological function. J Biol Chem 1995; 270: 27894 to 904.
40. von Heijne G, Liljeström P, Mikus P, Andersson H, Ny T. The efficiency of the uncleaved secretion signal in the plasminogen activator inhibitor type 2 protein can be enhanced by point mutations that increase its hydrophobicity. J Biol Chem 1991; 266: 15240-43.